Peer-reviewed veterinary case report
Ultrasound shows vincristine slows dog stomach, mosapride helps
By Tsukamoto, A et al.·Published in Journal of veterinary internal medicine·2011·Department of Veterinary Internal Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Ultrasonographic evaluation of vincristine-induced gastric hypomotility and the prokinetic effect of mosapride in dogs.
- Species:
- dog
Plain-English summary
Five healthy Beagle dogs were given vincristine, a medication that can slow down stomach movement, and they showed signs of decreased appetite, vomiting, and diarrhea. After treatment, the dogs were given a prokinetic medication called mosapride, which helps improve stomach motility. When mosapride was used alongside vincristine, the dogs experienced fewer gastrointestinal issues and their stomach movement returned to normal levels. This suggests that mosapride can help prevent some of the stomach problems caused by vincristine in dogs.
People also search for: dog vomiting after vincristine · prokinetic medication for dogs · Beagle stomach issues treatment
Abstract
BACKGROUND: Vincristine induces gastrointestinal motility disorders in humans. Adverse gastrointestinal events are commonly observed in dogs receiving vincristine. OBJECTIVES: To evaluate gastric motility after vincristine administration in dogs and the prophylactic effect of a prokinetic agent, mosapride. ANIMALS: Five healthy Beagle dogs. METHODS: Five dogs received vincristine i.v. at a dosage of 0.75 mg/m(2). The motility index (MI) of the antral contraction was ultrasonographically evaluated 30 minutes postfeeding before administration of vincristine and for 6 days after vincristine treatment. After a 6-week washout period, the dogs received vincristine with mosapride (2 mg/kg p.o., q24h for 6 days), and the MI was re-evaluated. Adverse gastrointestinal events were evaluated according to the Veterinary Co-operative Group Common Terminology Criteria for Adverse Events (VCOG-CTCAE). RESULTS: After vincristine administration, a significant decrease (P < .05) in MI was observed on days 3 (6.64 ± 0.30) and 4 (8.02 ± 0.94), compared with pretreatment levels (10.00 ± 0.62). Gastrointestinal adverse events were observed in 4 dogs (grade 2 decreased appetite: 3 dogs; grade 1 vomiting: 2 dogs; and grade 1 diarrhea and grade 2 hematochezia: 1 dog). When mosapride citrate was administered with vincristine and for the next 5 days, no decrease in MI was observed. Furthermore, adverse gastrointestinal events occurred less frequently (grade 1 vomiting and grade 2 hematochezia in 1 dog each). CONCLUSIONS AND CLINICAL IMPORTANCE: Vincristine (0.75 mg/m(2)) induces gastric hypomotility in dogs. Preventive administration of mosapride citrate (2.0 mg/kg p.o., q24h) improves hypomotility and may decrease the adverse gastrointestinal effects of vincristine.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22092644/